Enzolytics Inc (ENZC)

[falon]

From the 10Q:

The Company is in the final development of the recombinant of the parent anti-HIV monoclonal antibody (identified as “Clone 3”) which has been shown in in vitro tests conducted in 5 international laboratories to fully neutralized over 95% of all strains and viral subtypes of HIV-1 against which it was tested. The basis for its broad-spectrum efficacy is the fact that Clone 3 antibody targets an immutable epitope on the HIV virus. The targeted epitope has remained present in 98% (either directly or by way of conserved substitutions) of the 87,336 HIV isolates now known which have been analyzed by the Company using Artificial Intelligence (AI).

While the Company’s HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS, they may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current antiretroviral therapy for several significant reasons:

(1) the therapy will be non-toxic (without damage to the kidneys and liver) and will not cause bone densitydeterioration (osteopenia and osteoporosis) – as does antiretroviral treatments, (2) will not require lifetime treatment and (3) will be far less expensive.